This inventor holds 2 USPTO granted patents, plus 1 CIPO patent. Top assignees: Genesis Systems LLC, Other. Active years: 1990-1992.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1990-1992
Title: The Innovations of Philip G Meyers
Introduction
Philip G Meyers is an accomplished inventor based in Mequon, WI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of premenstrual syndrome. With a total of 2 patents, his work has the potential to improve the quality of life for many individuals.
Latest Patents
Meyers' latest patents focus on a method and dosage form for the treatment of premenstrual syndrome. The first patent describes a pharmaceutical composition suitable for oral administration that comprises micronized progesterone in an oil vehicle high in glycerides of polyunsaturated fatty acids. This innovative formulation allows for better absorption of micronized progesterone particles into the bloodstream, achieving high progesterone blood serum levels. The composition can be readily formulated into capsules for effective treatment. The second patent reiterates this method, emphasizing the same composition and its benefits for individuals suffering from premenstrual syndrome.
Career Highlights
Throughout his career, Philip G Meyers has worked with various companies, including Genesis Systems LLC. His expertise in pharmaceutical formulations has positioned him as a valuable contributor to the industry.
Collaborations
Meyers has collaborated with notable individuals such as Wayne S Maxson and Joel T Hargrove. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.
Conclusion
Philip G Meyers is a notable inventor whose work in the treatment of premenstrual syndrome showcases his innovative spirit and dedication to improving healthcare solutions. His contributions through his patents reflect a commitment to advancing pharmaceutical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile